Idiopathic inflammatory myopathies are heterogeneous in their pathophysiologic features and prognosis. The emergence of myositis-specific autoantibodies suggests that subgroups of patients exist.
T he idiopathic inflammatory myopathies (IIM) are a group of acquired myopathies characterized by muscle inflammation that are associated with motor weakness of varying severity. They are rare autoimmune diseases 1 and heterogeneous in their muscle phenotype and extramuscular manifestations.
The historical classification systems of myositis initially included 2 main entities: dermatomyositis (DM) and polymyositis (PM). 2, 3 Later, it was shown that PM was overvalued. 4, 5 Pathologic criteria were refined to isolate 2 new subgroups: inclusion body myositis (IBM) 6,7 and immune-mediated necrotizing myopathy (IMNM). 7 Each approach defines overlapping entities; for instance, antisynthetase syndrome is classified as both DM or PM. [8] [9] [10] A new classification system is beneficial to reduce confusion. Ideally, subgroups should share common characteristics in terms of phenotype, prognosis, and pathogenesis. Future clinical trials should be adapted on the basis of those subgroups.
There is increasing evidence that myositis-specific antibodies (MSA) or myositis-associated autoantibodies can help define subgroups of patients in terms of clinical or pathologic phenotypes, prognosis, and response to treatment. [11] [12] [13] [14] [15] We sought to propose a new classification system for IIM by performing unsupervised hierarchical clustering analysis, which permitted the aggregation of patients with IIM into 4 subgroups.
Methods

Study Design and Participants
This was an observational, retrospective, and multicentric study. A written waiver of informed consent was granted for 8 patients lost to follow-up via a letter sent to the patients defining nonobjection to study their retrospective anonymous data as part of research on myositis.
Data Collection
We developed an observational computerized database with electronic case report forms built with Voozanoo (EpiConcept) that included characteristics of the muscular and extramuscular manifestations (eTable 1 in the Supplement). As declared by the French legislation, race/ethnicity (relevant for myositis phenotype) was collected by the physicians (E.H., F.M., A.M., A.T., Y.A., and O.B.).
Detection of Antinuclear Antibodies and MSAand Myositis-Associated Antibodies
Step 2 was an analytical phase seeking to define subgroups and to build a new classification. A multiple correspondence analysis was used as a multivariate statistical method for description to reduce the dimensions of the data set (eFigure 1 in the Supplement). A hierarchical cluster analysis from the multiple correspondence analysis was used to determine subgroups of patients according to various characteristics. The clustering of patients was performed using Euclidean distance and the Ward agglomerative method. Crude associations were performed between the different variables that participated in the construction and those that were positioned with clusters identified by the hierarchical cluster analysis.
Step 3 sought to construct a decisional algorithm tree to easily position the participants in the new classification scheme. We used classification and regression trees. We performed cross-validation to select the optimal tree and performed multiple runs to avoid overfitting. The selection of the best tree was defined by jointly visualizing the smallest cross-validated prediction error on the training set associated with the highest proportion of correct classification on the test set. The classification quality of the tree was judged on the basis of the sensitivity and specificity estimation of classification criteria.
Step 4 involved the external validation of the model of classification from an independent data set (including patients from other centers). A naive classification of these patients obtained from the hierarchical cluster analysis was compared with the objective classification from the tree resulting from the initial set. The agreement between the 2 classifications was evaluated by Cohen κ light analysis, and the 95% CI was calculated from the empirical distribution by bootstrap analysis. ) with 708 variables were described (eTable 3 in the Supplement). Forty-seven discriminant variables were selected according to their relevance for distinguishing historical entities (PM, DM, and IBM) and/or their agreement with clinical practice from the point of view of expert physicians (Y.A. and O.B.). Ultimately, 260 patients (163 [62.7%] women; mean age, 59.7 years; median age [range], 61.5 years [48-71 years]) with no missing data for the 47 selected variables were included for the construction of the new classification system, starting with the multiple correspondence analysis (eFigures 1-3 and eTable 4 in the Supplement). We chose to perform multiple correspondence analysis on the first 39 dimensions, cumulatively explaining 90.4% of the variance. Then, we performed hierarchical clustering to identify clusters ( Figure 1) . The hierarchical tree suggested a partition into 4 clusters. Forty-one variables were discriminant for the hierarchical cluster analysis (eTable 5 in the Supplement). In addition to the description of the 41 selected variables, we also positioned relevant clinical-biological variables that were not used for hierarchical cluster analysis. These variables were excluded from the construction of the new classification scheme because of missing data (eg, newly available MSA dosages) or their potential weight in the classification in terms of historical diagnosis (PM, DM, and IBM) and/or recent diagnosis (PM, DM, IBM, IMNM, and antisynthetase syndrome) (eTable 6 in the Supplement). Finally, we identified the following characteristics (skin lesions, biological, muscular and extramuscular, histological, sociodemographic, and final status as well as the diagnosis) among the 4 identified clusters (Table and eTables 
Results
New Classification System
Cluster Subgroups
Of 260 study patients, 77 patients (29.6%) were included in the first cluster, of whom 46 patients (59.7%; 95% CI, 47.9%-70.8%; P < .001) were male, 74 (96.1%; 95% CI, 89.0%-99.2%; P = <.001) were white, and 58 (75.3%; 95% CI, 64.2%-84.4%; P < .001) were at least 60 years of age at the time of diagnosis. There were few patients with skin lesions (8 [10.4%]; 95% CI, 4.6%-19.4%; P < .001). Muscular evaluation was done using the Medical Research Council 5-point (MRC5) scale, which is a scale of 0 to 5 with lower numbers indicating more weakness: 5, muscle contracts against full resistance; 4, strength reduced, but contraction can still move joint against resistance; 3, strength further reduced such that joint can be moved only against gravity with examiner's resistance completely removed; 2: muscle can only move if resistance of gravity is removed; 1, only a trace or flicker of movement is seen or felt, or fasciculations are observed; and 0, no movement. were the variables that most characterized cluster 1 (greater V test value and smaller P value) (eTable 7 in the Supplement). By positioning the variables, cluster 1 regrouped mainly IBM (93.5% 95% CI, 85.5%-97.8%; P < .001).
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The 
Prediction of Clusters With Classification and Regression Tree
The best tree was obtained by removing variables related to muscle biopsy (eTable 5 and eFigures 4 and 5 in the Supplement), with 78.4% correct estimation using only the following 3 variables: DM rash (including Gottron papules), antisynthetase syndrome antibodies, and finger flexor scores of 3 or less ( Figure 2) . The classification quality of the tree was appreciated on the basis of all classification criteria, with an overall sensitivity of 77.0% (95% CI, 0.7%-0.8%) and a specificity of 92.0% (95% CI, 0.9%-0.9%).
External Validation
An independent set of patients (n = 50) in the myositis database, taken from different centers of the French myositis network, were used for external validation of our model. These patients fell into the 4 previously described clusters; the agreement between the 2 classification runs was excellent (Cohen κ light, 0.83; 95% CI, 0.65-0.96).
Discussion
This study identified 4 clusters emerging from unsupervised analysis. Each group corresponded to well-known entities, such as DM, IBM, IMNM, and antisynthetase syndrome. No unknown entity was revealed. The classification aggregated patients into subgroups based on epidemiologic, clinical, biological, serologic, and morphologic data. The decisional algorithm showed that MSA played a key role in estimating the connection to a cluster, whereas the pathologic data were dispensable.
To our knowledge, no study of a large group of patients with IIM seeking to establish subgroups without a priori knowledge has been performed. Of note, patients with IBM were also included, even if they could have been considered as a separate entity (based on degenerative characteristics).
7,18,19 They belonged to IIM and may have shared common features with patients with PM. 20 On the basis of the historical definition, patients with PM were present in the 4 clusters but mainly in clusters 2 (IMNM) and 4 (antisynthetase syndrome). This finding indicates that patients with PM do not represent a subgroup of patients and use of this term should probably be discontinued. Although the 4 clusters identified were associated with well-known entities, we identified new characteristics. The phenotypes of patients in cluster 1 matched with IBM 21-23 with regard to sociodemographic features (male, white, and older age at diagnosis), severe limb involvement (finger flexors and quadriceps), and typical histologic features (vacuolated fibers and mitochondrial abnormalities). For cluster 2, the pathologic characteristics of muscle (the absence of inflammation, with mainly necrosis) and the serologic markers (anti-SRP and anti-HMGCR antibodies) are associated with the definition of IMNM.
7
As previously reported, 24,25 those patients had lower limb involvement (psoas [MRC5 ≤ 3] whereas there was no involvement in the quadriceps) that was more severe than for patients in the other 3 clusters. Patients in cluster 3, corresponding to DM (based on the skin change 7 ), had more severe involvement of the upper limbs (deltoids [MRC5 ≤ 3]). Finally, patients in cluster 4, corresponding to antisynthetase syndrome, appeared to be a group distinct from those with DM, although antisynthetase syndrome was still frequently considered to be an entity overlapping with DM or PM 10-12 based on clinical criteria (Gottron papules and mechanic hands) or pathologic criteria (perifascicular atrophy). Antisynthetase syndrome was the least severe disease for muscle deficits, whereas CK levels were the most elevated with IMNM. Our study was complementary to the work of Lundberg et al 26 that aimed to respond to the question, "Does this patient suffer from a myositis?" whereas we aimed to stress the question, "What kind of myositis does the patient have?"
American College of Rheumatology/European League Against Rheumatism diagnosis criteria defined a novel probabilityscore model to diagnose patients with IIM from among a group of patients with myositis and without myositis. If they also aimed to classify the major subgroups of patients with IIM using a classification tree approach, they acknowledged a limited number of IMNM cases in their study, 27 which explains why they only predicted 3 subgroups of IIMs: DM (including juvenile and amyopathic subgroups), PM, and IBM. Our study completed the American College of Rheumatology/European League Against Rheumatism classification criteria by showing the presence of 4 entities comprising the IIM group. We did not define diagnosis criteria. The decisional algorithm was used to highlight the most relevant variables estimating the appurtenance to a subgroup but was not designed for clinical practice. We recommend the use of the established diagnosis criteria for these 4 IIM subgroups. 9,23,27,28 The algorithm showed that MSA were crucial for IIM classification and were probably more relevant than morphologic data in a large number of cases (eFigure 5 in the Supplement).
We noted that MSA known to be associated with IIM subgroups 13,15,29 fell into the corresponding clusters. This emphasizes that muscle biopsy may no longer be necessary for diagnosis of IIM in patients with MSA and corresponding phenotypes. Dermatologists and pneumologists already do not consistently perform a muscle biopsy when the clinical phenotype and MSA are clinical characteristics. In addition, the latest definition of IMNM showed that muscle biopsy is no longer required to diagnose IMNM in the presence of either anti- 
A pruned model was built (ie, by cutting terminal branches, a number of smaller and less complex trees was derived from the maximal previous tree) (information on the tree is given in the Statistical Analysis subsection of the Methods section). Dermatomyositis (DM) rash includes Gottron papules, periungual erythema, purplish rash, holster sign, and eruption on the dorsal hands. MRC5 indicates Medical Research Council 5-point scale (scale of 0 to 5 with lower numbers indicating more weakness).
Development 
Limitations
Although the external validation confirmed the classification in 4 subgroups among IIM, the number of patients included remains small (n = 50). Moreover, the classification was built with only 5 MSA (those tested in all patients) and needed to be amended and made accurate with a large collection of the new MSA, notably for the seronegative patients. The algorithm created with the classification tree cannot be applied to patients without myositis. It remains an epidemiologic tool in intrasyndromic patients to identify the best predictors of the subgroups. The prediction rates of the subgroups did not reach 100% but an optimal and parsimonious model with minimal elements was presented, taking in account the best prediction rates and reduction of overlapping between subgroups.
Conclusions
This study highlighted the characteristics of IIM subgroups, and the classification and regression trees method showed the variables to predict the adjoining group but did not define diagnostic criteria. Finally, these findings suggest the association of this new classification with prognosis and new therapeutic approaches in IIM warrants further study. 
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Skin lesions variables
skin lesions criteria, shawl signs, typical DM skin rash (including gottron's papules, periungual erythema, purplish rash, eruption on the dorsal hands and holster sign), heliotrope rash, alopecia, calcinosis, limb edema, panniculitis, skin ulcers and mechanic's hands Biological variables CK level (the highest), the presence of autoantibodies at least one time in the past history (MSA and MAA). Histological variables necrotic fibers, mitochondrial abnormalities, perifascicular atrophy, vacuolated fibers, muscular inflammation, invaded fibers and perivascular infiltrates Muscular clinical variables muscular symptoms, assessment of muscle strength (proximal, axial and distal muscles, at the most serious in disease history) with the manual testing according to MRC 5-points scale*, Barre test (the patient have to stretch his arms in front, hands in the same horizontal plane, maximum value/time: 150s), Minggazini test (the patient, in supine position, flexed the hip and legs in a 90 degree angle from the bed, maximum value/time: 75s), mobility, muscle biopsy and muscle MRI at the diagnosis Extra-muscular variables Extra muscular disorders variables were: lung disease with chest CT scan and functional respiratory tests at worst, cardiac disease, rheumatic disorder (arthralgia/arthritis), Raynaud's phenomenon, gastrointestinal involvement, renal impairment, thromboembolic diseases, synchronous cancer (±3 years of the myositis), infectious history, environmental factors and treatments in the past.
Final state
Finally a « final status » page, corresponding to the patient's news during the last visit (on site or not), or data on vital status for patients lost of follow up in French territory (contacts with hospitals centers, referring physicians and the birth city hall), with patient outcome and mortality (reason of death). 
